US FDA classifies dressings containing pDADMAC as Class II
This article was originally published in RAJ Devices
Executive Summary
The US Food and Drug Administration is classifying wound dressings that contain the additive poly (diallyl dimethyl ammonium chloride) as Class II devices and has issued a guidance document on special controls that must be followed by manufacturers intending to market such products1-3.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.